Clinical trial

Bioavailability and Bioequivalence Between Two Active Pharmaceutical Ingredient (API) Sources of Opicapone (OPC)

NCT04265027

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2018-02-20

PhasePHASE1

Study timeline

Study start (actual)2018-02-20Date precision: day

Registry last updated2020-02-11

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Parkinson Diseaseunresolved

Interventions

50 mg BIA 9 1067DRUG

25 mg BIA9 1067DRUG

50 mg OngentysDRUG

25 mg OngentysDRUG

Sponsors & collaborators

Bial - Portela C S.A.lead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04265027 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.